Time from symptoms onset to remdesivir is associated with the risk of ICU admission: a multicentric analyses
Abstract Background Shorter duration of symptoms before remdesivir has been associated with better outcomes. Our goal was to evaluate variables associated with the need of ICU admission in a cohort of hospitalized patients for COVID-19 under remdesivir including the period from symptoms onset to rem...
Үндсэн зохиолчид: | Rodrigo Alonso-Navarro, Margarita Ramírez, Mar Masiá, Roger Paredes, Rocío Montejano, Marina Povar-Echeverria, Jordi Carratalà, Miguel Salavert, Enrique Bernal, Carlos Dueñas, Juan Flores, Francisco Fanjul, Isabel Gutiérrez, Verónica Rico, Lourdes Mateu, Julen Cadiñanos, Juan Berenguer, Alex Soriano |
---|---|
Формат: | Өгүүллэг |
Хэл сонгох: | English |
Хэвлэсэн: |
BMC
2023-05-01
|
Цуврал: | BMC Infectious Diseases |
Нөхцлүүд: | |
Онлайн хандалт: | https://doi.org/10.1186/s12879-023-08222-y |
Ижил төстэй зүйлс
Ижил төстэй зүйлс
-
Remdesivir administration for SARS-CoV-2 pneumonia in ICU and non-ICU patients: outcome and posttreatment differences — the Italian Military Hospital experience
-н: Antonio Sabba, зэрэг
Хэвлэсэн: (2023-09-01) -
The effect of remdesivir on mortality and the outcome of patients with COVID‐19 in intensive care unit: A case–control study
-н: Mehran Amirizadeh, зэрэг
Хэвлэсэн: (2023-11-01) -
The use of Remdesivir in pregnant women with COVID-19
-н: Gulbanu Shaimerdenova, зэрэг
Хэвлэсэн: (2023-02-01) -
Remdesivir for coronavirus 2019 (COVID-19): More promising but still unproven
-н: Richard D. Shih, зэрэг
Хэвлэсэн: (2020-12-01) -
Publicaciones sobre hidroxicloroquina y remdesivir: actualización septiembre 2020
-н: Flor álvarez de Toledo
Хэвлэсэн: (2020-10-01)